Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5317-5324

  Kukowska Latallo, Jolanta F ^a   Candido, Kimberly A ^a,b   Cao, Zhengyi ^a   Nigavekar, Shraddha S ^a   Majoros, Istvan J ^a   Thomas, Thommey P ^a   Balogh, Lajos P ^a   Khan, Mohamed K ^a,c   Baker Jr , James R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CARBOXYTETRAMETHYLRHODAMINE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DENDRIMER; DRUG CARRIER; FLUORESCEIN; FOLATE RECEPTOR; FOLIC ACID; METHOTREXATE; NANOPARTICLE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEHYDRATION; DRINKING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RESPONSE; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; LIVER; MOUSE; MUSCLE WEAKNESS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; FLUORESCENT DYES; HUMANS; KB CELLS; METHOTREXATE; MICE; MICE, NUDE; MICE, SCID; NANOSTRUCTURES; POLYAMINES; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; TRITIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20444445144     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3921     Document Type: Article

References (36)

1. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-41.
2. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992;52:76708-11.
3. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329-38.
4. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
5. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43.
6. Antony AC, Kane MA, Portillo RM, Elwood PC, Kolhouse JF. Studies of the role of a participate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem 1985;260: 14911-7.
7. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233:134-44.
8. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995; 92:3318-22.
9. Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target 1994;2:101-12.
10. Rund LA, Cho BK, Manning TC, Holler PD, Roy EJ, Kranz DM. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int J Cancer 1999;83:141-9.
11. Cho BK, Roy EJ, Patrick TA, Kranz DM. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjug Chem 1997;8: 338-46.
12. Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci U S A 1995;92:9057-61.
13. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 1996;30:53-65.
14. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA, Baker JR Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 1996;24:2176-82.
15. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A 1996;93:4897-902.
16. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999;10:767-76.
17. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol 1997;32:748-54.
18. 125I-labelled polyamide-amine dendrimers in vivo. J Control Release 2000;65:133-48.
19. Delong R, Stephenson K, Loftus T, et al. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci 1997;86:762-4.
20. Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002;19:1310-6.
21. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 2004; 21:476-83.
22. Majoros I, Keszler B, Woehler S, Bull T, Baker J. Acetylation of poly(amidoamine) dendrimers. Macromolecules 2003;36:5526-9.
23. Wilbur DS, Pathare PM, Hamlin DK, Buhler KR, Vessella RL. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug Chem 1998;9:813-25.
24. Turek JJ, Leamon CP, Low PS. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci 1993;106:423-30.
25. Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Green MA. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med 1998;39:1579-85.
26. Belz S, Nau H. Determination of folate patterns in mouse plasma, erythrocytes, and embryos by HPLC coupled with a microbiological assay. Anal Biochem 1998;265:157-66.
27. Nelson BC, Pfeiffer CM, Margolis SA, Nelson CP. Solid-phase extraction-electrospray ionization mass spectrometry for the quantification of folate in human plasma or serum. Anal Biochem 2004;325:41-51.
28. Thomas TP, Myaing MT, Ye JY, et al. Detection and analysis of tumor fluorescence using a two-photon optical fiber probe. Biophys J 2004;86:3959-65.
29. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551-61.
30. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000;26:269-86.
31. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-7.
32. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4.
33. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
34. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65: 271-84.
35. Thomas TP, Majoros IJ, Kotlyar A, et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. In press 2005.
36. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83.